...
首页> 外文期刊>The Analyst >Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2nanoparticle deposited capillary column
【24h】

Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2nanoparticle deposited capillary column

机译:使用MALDI-TOF MS结合TiO2纳米颗粒沉积毛细管柱分离和富集磷酸肽的蛋白激酶抑制剂筛选

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A MALDI-TOF mass spectrometric method for rapid screening of protein tyrosine kinase (PTK) inhibitors has been developed. To circumvent the ion suppression of phosphorylated substrate peptides caused by the presence of high abundant non-phosphorylated peptides in the enzymatic reaction mixtures, a separation and enrichment process of the phosphorylated peptides from complex mixtures was carried out by using an in-house fabricated TiO2nanoparticle -coated capillary column prior to the MS analysis. With a synthetic phosphopeptide (DAIpYAAPFAKKK), of which the sequence is similar to that of the substrate (EAIYAAPFAKKK) of the Abelson tyrosinekinase (Abl), as the internal standard, the signal ratio of the phosphorylated substrate to the standard detected by MALDI-TOF MS is linearly correlated with the molar ratio of the two phosphopeptides over the range of 0.3 to 3 with r2 = 0.99. We validated the MS method by determining the IC50 value of imatinib, an Abl inhibitor for clinical treatment of chronic myelogenous leukaemia (CML). The obtained IC50 value (234 nM) is consistent with that determined by ELISA (291 nM). Then, six analogues of imatinib synthesized in our laboratory were screened using the method, giving rise to inhibitory potential results which are in good agreement with the docking analysis data. The developed method is sensitive, operationally simple, does not require isotope-labelling and is cost/time effective, providing an alterative method for rapid screening of PTKinhibitors as therapeutic agents for tumours.
机译:已经开发了用于蛋白质酪氨酸激酶(PTK)抑制剂快速筛选的MALDI-TOF质谱方法。为了避免由于酶促反应混合物中存在大量丰富的非磷酸化肽而引起的磷酸化底物肽的离子抑制,使用内部制备的TiO2纳米颗粒-从复杂混合物中分离和富集了磷酸化肽-进行MS分析之前,先用毛细管电泳柱以其序列与Abelson酪氨酸激酶(Abl)的底物(EAIYAAPFAKKK)序列相似的合成磷酸肽(DAIpYAAPFAKKK)作为内标,通过MALDI-TOF检测到磷酸化底物与标准品的信号比MS与两种磷酸肽的摩尔比在0.3至3的范围内线性相关,r2 = 0.99。我们通过确定伊马替尼(一种用于临床治疗慢性粒细胞性白血病(CML)的Abl抑制剂)的IC50值验证了MS方法。获得的IC50值(234 nM)与ELISA测定的IC50值(291 nM)一致。然后,使用该方法筛选了在我们实验室中合成的伊马替尼的六种类似物,从而产生了与对接分析数据高度吻合的抑制潜力结果。所开发的方法灵敏,操作简单,不需要同位素标记且具有成本/时间效益,为快速筛选作为肿瘤治疗剂的PTK抑制剂提供了另一种方法。

著录项

  • 来源
    《The Analyst》 |2010年第11期|p.2858-2863|共6页
  • 作者单位

    aBeijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190. E-mail: fuyi.wang@iccas.ac.cn, Fax: +86-10-62529069, Tel: +86-10-62529069bCollege of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, China,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号